Company news
Enliven Therapeutics, Inc. news in 2024
Enliven Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
November 6, 2024
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
September 27, 2024
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
September 17, 2024
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
August 12, 2024
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
May 28, 2024
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
April 10, 2024
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
April 8, 2024
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
March 27, 2024
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
March 18, 2024
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 13, 2024
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
February 26, 2024
Decks in 2024
- Technical Presentation (April 2024)
Technical · 51 slides · Apr 11, 2024